Zobrazeno 1 - 7
of 7
pro vyhledávání: '"Rainer, Kobelt"'
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Kaan Kavakli, Marianne Hoffmann, Rosario Perez Garrido, Amy L. Dunn, Angelo Claudio Molinari, Karin Fijnvandraat, Amy D. Shapiro, Karin Kurnik, Chris Barnes, Nadine G. Andersson, Rainer Kobelt, Runhui Wu, Anne Mäkipernaa, Gili Kenet, Marilyn J. Manco-Johnson, Maria Elisa Mancuso, Ri Liesner, Manuel Carcao, Beatrice Nolan, Helen Platokouki, Rolf Ljung, Pia Petrini, Günter Auerswald
Publikováno v:
British journal of haematology, 179(2), 298-307. Wiley-Blackwell
The discussion of prophylactic therapy in haemophilia is largely focused on joint outcomes. The impact of prophylactic therapy on intracranial haemorrhage (ICH) is less known. This study aimed to analyse ICH in children with haemophilia, with a focus
Autor:
Jacky K. Yu, Alfonso Iorio, Andrea N. Edginton, Sanjay Ahuja, Ma Teresa Álvarez Román, Ma E. Arrieta, Mikko Arola, Giovanni Barillari, Vinod Balasa, Mark Belletrutti, Ruben Berrueco Moreno, Philippe Beurrier, Cristoph Bidlingmaier, Victor Blanchette, Jan Blatny, Santiago Bonanad, Kelsey Brose, Deborah Brown, Paulette C. Byant, Mariana Canaro, Manuela Carvalho, Cristina Catarino, Meera Chitlur, Erin Cockrell, Pratima Chowdary, Marjon Cnossen, Peter Collins, Michial Coppens, Stacy Croteau, Dorina Cultrera, Raimundo de Cristofaro, Emmauelle de Raucourt, Dominique Desprez, Amy Dunn, Magda El‐Ekiabi, Barbara Faganel Kotnik, Kathleen Fischer, Brigit Frotscher, Susana Garbiero, Raquel Garrido Ruiz, Joan Gill, Carmen Gomez del Castillo, Saskia Gottstein, Giuseppe Lassandro, Paola Giordano, Daniel Hart, Inga Hegemann, Cedric Hermans, Baolai Hua, Nina Hwang, Shannon Jackson, Paula James, Olga Katsarou, Kaan Kavakli, Christine Kempton, Karim Kentouche, Osman Khan, Rainer Kobelt, Rebecca Kruse‐Jarres, Edward Laane, Eric Larson, Riitta Lassila, Adrienne Lee, Man‐Chiu Poon, Jennifer Lissick, Satu Langstrom, Johnny Mahlangu, Michael Makris, Emmanuela Marchesini, Jose Mateo, Pacual Marco Vera, Marta Martorell, Tadashi Matsushita, Simon McCrae, Eva Mignot‐Castellano, Caitlin Montcrieff, Philip Maes, Veerle Mondelars, Marlies Bekart, Elena Mora, Juan Cristóbal Morales, Guillaume Mourey, Marie Ann Bertrand, Mariasanta Napolitano, Sergio Siragusa, Claude Negrier, Daniela Neme, Ritta Niinimaki, Johannes Oldenburg, Thilo Albert, Deborah Ornstein, Margarete Ozelo, John Carl Panetta, Ellis J. Neufeld, Stephanie P'Ng, Kathelijne Peerlinck, Berardino Pollio, Claire Pouplard, Yves Gruel, Alessandra Prezotti, Vicky Price, Fitri Primacakti, Mathieu Puyade, Paolo Radossi, Leslie Raffini, Margaret Ragni, Savita Rangarajan, Mark T. Reding, Robin Reid, Jose Restrepo, Jose Ramirez, Michael Recht, Manuel Rodriguez Lopez, Arlette Ruiz‐Sàez, Mahasen Saleh, Amy Shapiro, Anjali Sharathkumar, Anna Selmeczi, Mindy Simpson, Tami Singleton, Maria Sol Cruz, Veronica Soto, MacGregor Steele, Werner Streif, Hao Wei Sun, Bruce Ritchie, Jing Sun, Xiaqin Feng, Takashi Suzuki, Asuza Nagao, Cliff Takemoto, Heather Tapp, Jerry Teitel, Alan Tinmouth, Courtney Thornburg, Alberto Tosseto, Oliver Turnstall, Catherine Vezina, Beth Warren, Allison Wheeler, Juan D. Wilches Gutierrez, John K.M. Wu, Tung Wynn, Renchi Yang, Guy Young, Ezio Zanon, Irena Zupan
Publikováno v:
Research and practice in thrombosis and haemostasis, Vol. 3, no.3, p. 528-541 (2019)
Research and Practice in Thrombosis and Haemostasis
Research and Practice in Thrombosis and Haemostasis, Vol 3, Iss 3, Pp 528-541 (2019)
Research and Practice in Thrombosis and Haemostasis
Research and Practice in Thrombosis and Haemostasis, Vol 3, Iss 3, Pp 528-541 (2019)
The objective of this scoping review is to summarize the current use of pharmacokinetics for tailoring prophylaxis in hemophilia patients switching between clotting factor products. Patients with hemophilia may require switching of clotting factor co
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8855ec59f7541838e90c9de25930d966
https://hdl.handle.net/2078.1/224098
https://hdl.handle.net/2078.1/224098
Autor:
Elena Santagostino, Carmen Escuriola, Manuela Carvalho, Nadine Gretenkort-Andersson, Anne Rafowicz, Helen Platokouki, Manuel Carcao, Susanna Ranta, Beatrice Nolan, Christoph Koenigs, Torben Stamm Mikkelsen, Claudio Molinari, Rolf Ljung, Michael D. Williams, Liz Chalmers, Krista Fischer, Marijke Van den Berg, Ana Rosa Cid, Rainer Kobelt, Hervé Chambost, Christoph Male, Gili Kenet, Georges E. Rivard, Carmen Altisent, Teresa Álvarez-Roman, Ri Liesner, Karin Kurnik, Christel Van Geet, Martina Buehrlen, Ségolène Claeyssens, Johannes Oldenburg, Anne Mäkipernaa
Publikováno v:
Blood. 132:2472-2472
Introduction.In patients with hemophilia treated with factor VIII products, the development of inhibitory antibodies poses the largest safety risk. Especially during the first 50 exposure days (EDs), up to 37% of patients with severe hemophilia A hav
Autor:
Tin Tin Yee, Johannes Oldenburg, Anne Mäkipernaa, Elena Santagostino, Ana Rosa Cid, Anne Rafowicz, Manuel Carcao, Beatrice Nolan, Angelo Claudio Molinari, Maria Elisa Mancuso, Rolf Ljung, Pia Petrini, Christel Van Geet, Carmen Escuriola, Rainer Kobelt, Angela Thomas, Helen Platokouki, Rosario Perez-Garrido, Georges-Etienne Rivard, Marijke van den Berg, Krista Fischer, Michael Williams, Guenter Auerswald, Gili Kenet, Hervé Chambost, Elizabeth Chalmers, Carmen Altisent, Christoph Königs, Teresa Álvarez-Roman, Karin Kurnik, Raina Liesner
Publikováno v:
Blood. 128:3774-3774
The development of anti-FVIII antibodies (i.e., inhibitors) is the major side effect of severe hemophilia A treatment. Inhibitors mainly develop in children during the first 50 exposure days and are classified in low-and high-titer (i.e., peak titer
Autor:
K. Kurnik-Auberger, Ségolène Claeyssens, A. Glomstein, C. Van Geet, Owen P. Smith, Wolfgang Muntean, F. Hill, L. Rosado, E Scheibel, M. Siimes, Ian Hann, P Petrini, W. Kreuz, Hervé Chambost, Rolf Ljung, G. Mancuso, J. M. Tusell, Rainer Kobelt, S. Aronis-Vournas, M. van den Berg
Publikováno v:
Haemophilia. 6:619-624
A survey was made of the current status of treatment of haemophilic boys at 20 centres in 16 European countries and includes approximately 1500 of the estimated 6500 haemophiliacs in the participating countries. Many mild haemophiliacs are not seen,
Autor:
G. Auerswald, Carmen Altisent, F. A. Scaraggi, V. Rossi, Jan Blatny, G. F. Rivolta, Massimo Morfini, Rainer Kobelt, A. Borel-Derlon, J. Rodriguez-Martorell
Publikováno v:
Haemophilia : the official journal of the World Federation of Hemophilia. 13(5)
Many patients with haemophilia develop inhibitors to factor VIII and require bypassing agents to provide haemostatic cover for limb- or life-threatening bleeding episodes. Due to the reduced risk of blood-borne pathogen transmission with recombinant